These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19442951)

  • 1. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.
    Nakazawa G; Vorpahl M; Finn AV; Narula J; Virmani R
    JACC Cardiovasc Imaging; 2009 May; 2(5):625-8. PubMed ID: 19442951
    [No Abstract]   [Full Text] [Related]  

  • 2. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
    Finn AV; Nakazawa G; Kolodgie FD; Virmani R
    JACC Cardiovasc Interv; 2009 Apr; 2(4):300-2. PubMed ID: 19463440
    [No Abstract]   [Full Text] [Related]  

  • 3. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study.
    Higo T; Ueda Y; Oyabu J; Okada K; Nishio M; Hirata A; Kashiwase K; Ogasawara N; Hirotani S; Kodama K
    JACC Cardiovasc Imaging; 2009 May; 2(5):616-24. PubMed ID: 19442950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVUS and OCT: either or survivor ….
    Finn AV; Chandrashekhar Y; Narula J
    JACC Cardiovasc Imaging; 2011 Sep; 4(9):1047-9. PubMed ID: 21920345
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevo stent: a successful stent makeover.
    Belardi JA
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):52-3. PubMed ID: 21181969
    [No Abstract]   [Full Text] [Related]  

  • 7. Neointimal coverage over coronary stent struts crossing the side branch Ostia.
    Sakata Y
    Circ J; 2011; 75(1):51-2. PubMed ID: 21173501
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of very late stent thrombosis after drug-eluting stent implantation: findings from coronary angioscopy and optical coherence tomography.
    Ikenaga H; Ishihara M; Dai K; Nakama Y; Ohtani T
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1217-9. PubMed ID: 22093273
    [No Abstract]   [Full Text] [Related]  

  • 9. NEVO™: a new generation of sirolimus-eluting coronary stent.
    Falotico R; Parker T; Grishaber R; Price S; Cohen SA; Rogers C
    EuroIntervention; 2009 Dec; 5 Suppl F():F88-93. PubMed ID: 22100684
    [No Abstract]   [Full Text] [Related]  

  • 10. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
    Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal stent expansion and complete neointimal coverage: does this association make sense?
    Mintz GS; Choi SY
    JACC Cardiovasc Interv; 2009 Oct; 2(10):995-6. PubMed ID: 19850261
    [No Abstract]   [Full Text] [Related]  

  • 12. The "mini-crush" technique for managing bifurcation lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2009 Jul; 74(1):85-7. PubMed ID: 19530202
    [No Abstract]   [Full Text] [Related]  

  • 13. Another small step for small vessels.
    Morrison DA
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
    [No Abstract]   [Full Text] [Related]  

  • 14. A generation 2.5 drug-eluting stent?
    Ellis SG
    JACC Cardiovasc Interv; 2009 Oct; 2(10):986-8. PubMed ID: 19850259
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed neointimalization on drug-eluting stents--speculation from optical coherence tomography.
    Shite J
    Circ J; 2009 Dec; 73(12):2210-1. PubMed ID: 19940371
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The process of bringing new drug-eluting stents to market will they see the light of day?
    Holmes DR; Patel M
    JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral sirolimus after bare metal stent implantation: a glimpse to the future.
    Mieres J
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):158-9. PubMed ID: 20931667
    [No Abstract]   [Full Text] [Related]  

  • 20. The artisan approach for stenting bifurcation lesions.
    Colombo A; Latib A
    JACC Cardiovasc Interv; 2010 Jan; 3(1):66-7. PubMed ID: 20129571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.